Enlivex Therapeutics Secures China Patent Allowance for Sepsis Treatment
Ticker: ENLV · Form: 6-K · Filed: Mar 17, 2025 · CIK: 1596812
Sentiment: bullish
Topics: patent, intellectual-property, china, sepsis
TL;DR
China patent allowance for Enlivex's sepsis drug Allocetra – big win for IP!
AI Summary
On March 17, 2025, Enlivex Therapeutics Ltd. announced that the China National Intellectual Property Administration issued a notice of allowance for a patent related to its Allocetra immunotherapy. This patent, if granted, will cover the use of Allocetra for the treatment of patients with severe sepsis and septic shock.
Why It Matters
This patent allowance in China strengthens Enlivex's intellectual property portfolio for its lead drug candidate, potentially paving the way for future commercialization in a major market.
Risk Assessment
Risk Level: medium — While a patent allowance is positive, it is not a granted patent and faces further regulatory steps, and the commercial success of the drug is not guaranteed.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- China National Intellectual Property Administration (company) — Patent office
- Allocetra (drug) — Immunotherapy drug
- March 17, 2025 (date) — Announcement date
FAQ
What specific indication is covered by the China patent allowance for Allocetra?
The patent allowance covers the use of Allocetra for the treatment of patients with severe sepsis and septic shock.
Which regulatory body issued the notice of allowance?
The China National Intellectual Property Administration issued the notice of allowance.
When was this announcement made by Enlivex Therapeutics?
The announcement was made on March 17, 2025.
What is the name of Enlivex's lead immunotherapy drug candidate?
Enlivex's lead immunotherapy drug candidate is named Allocetra.
What is the significance of this patent allowance for Enlivex?
The patent allowance strengthens Enlivex's intellectual property protection for Allocetra in China, a significant market.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on March 17, 2025 regarding Enlivex Therapeutics Ltd. (ENLV).